1.
Fumagalli C, Betella I, Ranghiero A, Guerini-Rocco E, Bonaldo G, Rappa A, Vacirca D, Colombo N, Barberis M. In-house testing for homologous recombination repair deficiency (HRD) testing in ovarian carcinoma: a feasibility study comparing AmoyDx HRD Focus panel with Myriad myChoiceCDx assay. Pathologica [Internet]. 2022Sep.22 [cited 2024Jul.16];114(4):288-94. Available from: https://www.pathologica.it/article/view/791